#Johnson & Johnson
-
Johnson & Johnson COVID-19 vaccine no longer available in U.S.
-
J&J unit files for second bankruptcy to pursue $8.9 billion talc settlement
-
Tunisia to stop using Johnson & Johnson COVID-19 vaccine
-
U.S. FDA limits use of Johnson & Johnson COVID-19 vaccine over blood clot risk
-
J&J suspends sales forecast for COVID-19 vaccine, cuts profit view
-
Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement
-
J.&J. Pauses Production of Its Covid Vaccine Despite Persistent Need
-
J&J expects up to $3.5 bln in COVID vaccine sales this year
-
J&J says its single dose protects against breakthrough COVID-19 for up to 6 months
-
U.S. study suggests COVID-19 vaccines may be ineffective against Omicron without booster
-
Georgia to receive Johnson&Johnson COVID-19 vaccine
-
Saudi Arabia approves Moderna's COVID vaccine
-
U.S. to send 3 million J&J COVID-19 vaccine doses to Brazil
-
EU foregoes 100 million J&J vaccines, considers donating other doses
-
Uzbekistan looks forward to receiving COVID-19 vaccines from US
-
U.S. administers 245.6 mln doses of COVID-19 vaccines
-
Moderna boosting COVID-19 vaccine capacity, targets up to 3 billion shots in 2022
-
J&J vaccine study to resume in South Africa on Wednesday
-
European countries to resume J&J COVID vaccine deliveries
-
South Africa suspends J&J vaccine rollout
-
Thailand approves Johnson & Johnson one-shot vaccine
-
J&J to make up to three billion COVID-19 vaccines in 2022: chief scientist
-
Biden takes steps to help Merck boost Johnson & Johnson COVID-19 vaccine supply
-
US regulator approves Johnson&Johnson coronavirus vaccine
